Newsgather
GeriSamsung Biologics Union Agrees to Return to Negotiation Table After First-Ever Strike
Samsung Biologics Union Agrees to Return to Negotiation Table After First-Ever Strike
Gelişiyor
Yonhap News03.05.2026Labor2 dk okumaSouth Korea

Samsung Biologics Union Agrees to Return to Negotiation Table After First-Ever Strike

Around 2,800 of 4,000 unionized workers continue three-day walkout demanding 14% pay hike and transparent personnel management

Hızlı Bakış

  • Samsung Biologics union has agreed to return to negotiations on Monday under labor ministry mediation, after its first-ever strike entered day three.
  • The union demands a 14% increase in base and performance pay, a 30 million won one-off cash incentive, and bonuses equal to 20% of annual operating profit.
  • The company has proposed 6.2% and claims the walkout could cause at least 640 billion won in damage, equivalent to half its Q1 sales.

Yapay zekâ özeti

Neden Önemli?

Samsung Biologics is a major biotech company and part of Samsung Group, the largest conglomerate in South Korea. This marks the first-ever union strike in the company's history, reflecting growing labor activism in Korea's corporate sector.

Yazı boyutu

SEOUL, May 3 (Yonhap) -- Samsung Biologics, the biotech arm of Samsung Group, has agreed to return to the negotiation table this week, a corporate official said. The two sides will renegotiate on Monday under the mediation of the Jungbu regional employment and labor office, after the first round of talks fell through on Thursday. The strike is the first ever for the union, with the walkout entering its third day on Sunday. "Our decision to respond to the labor ministry's arbitration request during the walkout was part of our sincere efforts to sort the issue out through dialogue," a company source said. The representative urged the labor union to stop its "irrational" demands and collective action and return to the negotiation table. During the first arbitration meeting held last week, the labor union reportedly demanded the company change all of its bargaining committee members as a prerequisite for talks. Unionized workers of Samsung Biologics have been staging a strike since Friday. They have demanded a 14 percent increase in both base and performance-related pay, a one-off cash incentive of 30 million won (US$20,389.9) per worker, and bonuses equivalent to 20 percent of annual operating profit. The company has proposed a combined 6.2 percent increase in base and performance pay. Around 2,800 of 4,000 unionized members have participated in the collective action, according to the company's labor union. The company claims the walkout could cause at least 640 billion won worth of damage, which is equivalent to around half of the company's sales for the first quarter. The union said it plans to continue the strike until Tuesday. Unionized workers of Samsung Biologics called for the company to establish "fair and transparent" personnel management standards. "What the labor union demands is that the management should exercise personnel and management authority in a transparent manner so that the employees can work while trusting the company," the labor union said in a release. The labor union is said to have proposed a collective bargaining agreement that includes clauses requiring prior consent by the union in regard to new hiring, personnel evaluations and decisions on mergers and acquisitions.

Bundan Sonra Ne Olabilir?

Yapay zekâ öngörüsü — kesinlik taşımaz

  • Negotiations will continue beyond Monday without immediate resolution

    Muhtemel · Günler içinde

  • Strike may extend beyond Tuesday if no agreement reached

    Olası · Günler içinde

  • Company may offer slightly higher wage increase to end dispute

    Muhtemel · Haftalar içinde

Açık Sorular

  • Will the union accept the company's 6.2% offer?
  • How long will the strike last?
  • Will the company agree to union demands on personnel management transparency?
  • What will be the actual financial impact of the strike?

İlgili Konular

Bu haber ilk olarak şurada yayınlandı: Yonhap News.

İlgili Haberler

Bu konuda daha fazlasamsung biologics